Patents Assigned to K.U. Leuven Research & Development
-
Publication number: 20100099869Abstract: This invention relates to a purine or pyrimidine phosphonate compound of formula (I) or pharmaceutically acceptable salt thereof; wherein B, X, and R1-R3 are as defined in classes and subclasses herein. These compounds may be used as antiviral precursors. The invention also relates to therapeutic compositions of these compounds and their use for the preparation of a medication for testing and/or preventing a viral infection in a patient. The invention also provides methods for making these compounds. In particular, the invention provides an H-phosphinate precursor intermediate of formula (II) wherein B is a purine or pyrimidine base as defined herein and R1 is selected from the group comprising a hydrogen atom, and a methyl, ethyl, hydroxymethyl, hydroxyethyl and C1-6haloalkyl group.Type: ApplicationFiled: November 8, 2007Publication date: April 22, 2010Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, UNIVERSITE DE LA MEDITERRANEE, K.U. LEUVEN RESEARCH & DEVELOPMENTInventors: Bruno Canard, Karine Alvarez, Karine Barral, Jean-Louis Romette, Johan Neyts, Jan Balzarini
-
Publication number: 20100074787Abstract: The invention provides a process of making porous structures or materials, including the colloidal processing (e.g. slip casting, pressure casting, tape casting or electrophoretic deposition) of solid particle emulsions to form a green body that can be directly sintered without a de-binding step.Type: ApplicationFiled: June 27, 2006Publication date: March 25, 2010Applicant: K.U. LEUVEN RESEARCH & DEVELOPMENTInventors: Bram NEIRINCK, Jozef VLEUGELS, Jan FRANSAER, Omer VAN DER BIEST
-
Publication number: 20100063059Abstract: A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided.Type: ApplicationFiled: July 6, 2007Publication date: March 11, 2010Applicants: Gilead Sciences, Inc., K. U. Leuven Research & DevelopmentInventors: Steven S. Bondy, Terrence C. Dahl, David A. Oare, Reza Oliyai, Winston C. Tse, Vahid Zia
-
Patent number: 7673498Abstract: In a first object the present invention provides a method for the inspection of the quality of the sealing of a packages and more specifically the method of the present invention allows the on-line inspection of the air-tightness of a package. Said method comprising the following steps of (i) acquiring the noise signal generated by the sealing equipment during the sealing of the package, (ii) analyzing the signal in order to determine the values of at least one physical parameter characterizing the noise signal and (iii) deciding on the quality of the sealing by comparing the determined value to a reference value for said physical parameter.Type: GrantFiled: May 7, 2004Date of Patent: March 9, 2010Assignee: K.U. Leuven Research and DevelopmentInventors: Josse De Baerdemaeker, Bart De Ketelaere, Bram Kamers
-
Patent number: 7666307Abstract: The invention provides a method for reducing the average size of biologically active compound particles or agglomerates suspended in a fluid by flowing one or more times said fluid having biologically active compound particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of a substantial portion of the biologically active compound particles or agglomerates by at least 25%. This method may be incorporated into a process for manufacturing a 10 biologically active compound formulation.Type: GrantFiled: August 25, 2004Date of Patent: February 23, 2010Assignee: K.U. Leuven Research & DevelopmentInventors: Guy Van Den Mooter, Johan Martens, Jan Nuyens
-
Publication number: 20100040816Abstract: The present invention provides silk fibre reinforced composite materials comprising a thermoplastic polymer matrix, which are relatively light, whilst having a high impact resistance. The silk fibre reinforced composite materials of the present invention allow for an optimal dissipation of the impact energy such that they have a penetration resistance higher than 20 J per mm of plate thickness, more preferably more than 30 J per mm, most preferably more than 40 J per mm. Due to the high impact resistance of the fibrous composite material according to the present invention, panels or shells comprising such composites are particularly useful for the manufacture of objects, which in the course of their life cycle are subject to shocks or at risk of penetration.Type: ApplicationFiled: March 26, 2007Publication date: February 18, 2010Applicant: K.U. LEUVEN RESEARCH AND DEVELOPMENTInventors: Ignace Verpoest, Aart Willem Van Vuure, Nedda El Asmar, Jan Vanderbeke
-
Patent number: 7648998Abstract: The present invention relates to a pharmaceutical composition for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general Formula (A) wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening ofcompounds according to the invention having above mentioned general Formula and their use in the treatment or prophylaxis of viral infections.Type: GrantFiled: December 21, 2004Date of Patent: January 19, 2010Assignees: K.U. Leuven Research & Development, Gilead Sciences, Inc.Inventors: Steven S. Bondy, Eric Davis Dowdy, Choung U. Kim, David A. Oare, Johan Neyts, Vahid Zia, Gerhard PĆ¼rstinger
-
CRYSTALLINE MESOPOROUS OXIDE BASED MATERIALS USEFUL FOR THE FIXATION AND CONTROLLED RELEASE OF DRUGS
Publication number: 20100008990Abstract: The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.Type: ApplicationFiled: July 6, 2009Publication date: January 14, 2010Applicant: K.U. Leuven Research & DevelopmentInventors: Johan Adriaan Martens, Christine Eva Antonia Kirschhock, Sebastien Philippe Brigitte Kremer, Alexander Jan Maria Herman Eugeen Aerts, Guy Van Den Mooter, Jan Van Humbeeck -
Publication number: 20090318282Abstract: A silicate-based microporous ceramic molecular sieve membrane zeolite-like properties with an ordered stack of nanometre-sized slab-shaped building blocks having zeolite framework. A method for producing a membrane does not involve a hydrothermal treatment step, hence avoiding the formation of zeolite crystals.Type: ApplicationFiled: October 19, 2006Publication date: December 24, 2009Applicants: VLAAMSE INSTELLING VOOR TECHNOLOGISH ONDERZOEK N.V. (VITO), K.U. LEUVEN RESEARCH & DEVELOPMENTInventors: Anita Buekenhoudt, Pierre Jacobs, Ivo Vankelecom, Johan Martens
-
Publication number: 20090311325Abstract: The present invention relates generally to use of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR, in the formulation of solid dispersions of low aqueous solubility and dissolution rate bioactive compound and, more particularly to a system and method for improving the solubility and dissolution rate of such low aqueous solubility and dissolution rate bioactive compound, in particular the drug of low aqueous solubility, such as a BCS Class II or Class IV drug compounds.Type: ApplicationFiled: April 10, 2007Publication date: December 17, 2009Applicant: K.U.LEUVEN RESEARCH AND DEVELOPMENTInventors: Sandrien Janssens, Guy Van Den Mooter
-
Publication number: 20090312660Abstract: A system and method are described for combining the respiratory status (e.g. amount and type of cough) with the localization of organisms having the respiratory status in real time. The organisms are able to suffer from a respiratory complaint, i.e. they have lungs such as mammals especially farm animals and humans. In particular the present invention is advantageous for animals and humans who are exposed to closed confinements such as pens, cages, aircraft, public places where humans are in close proximity to each other.Type: ApplicationFiled: June 17, 2008Publication date: December 17, 2009Applicants: BIORICS NV, K.U. LEUVEN RESEARCH & DEVELOPMENTInventors: Marcella Guarino, Sara Ferrari, Annamaria Costa, Federica Borgonovo, Daniel Berckmans, Jean-Marie Aerts, Mitchell Silva, Vasileios Exadaktylos, Toon Leroy
-
Patent number: 7629390Abstract: The invention relates to a method and a system for the emulsification of a pre-mix of two or more immiscible liquids by flowing or circulating one or more times said pre-mix through one or more magnetic fields.Type: GrantFiled: November 14, 2003Date of Patent: December 8, 2009Assignee: K.U. Leuven Research & DevelopmentInventors: Jan Nuyens, Johan Martens
-
Patent number: 7622259Abstract: The present invention relates to a method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib(?) (GPIb(?) and ristocetin, or a functionally equivalent substance. Additionally, the invention relates to the use of the aforementioned soluble form or portion of glycoprotein Ib(?), of ristocetin or a functional equivalent substance, of specifically reacting anti-GPIB(?) antibody(ies) and/or of specific binding partners, like specifically reacting anti-vWF antibody(ies) for carrying out the method of the invention. Furthermore, the present invention relates to kits for carrying out the method of the invention.Type: GrantFiled: July 5, 2000Date of Patent: November 24, 2009Assignee: K.U. Leuven Research & DevelopmentInventors: Nancy Cauwenberghs, Karen Vanhoorelbeke, Hans Deckmyn
-
Publication number: 20090274622Abstract: The invention relates to a method for obtaining an image of ischemic, infarcted or necrotic tissue in a subject, comprising the step of administering an imaging agent comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound. For example, the invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as necrosis or infarct specific agents. The phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives can be labeled with a radionuclide, a radiopaque material or a material enhancing the effects magnetic resonance imaging. The invention further features a pharmaceutical composition comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound optionally conjugated to a radionuclide or a radiopaque material, provided that said phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound is not mono-[123I]-iodohypericin.Type: ApplicationFiled: July 13, 2009Publication date: November 5, 2009Applicant: K.U. Leuven Research & DevelopmentInventors: Ni YICHENG, Guy Bormans, Guy Marchal, Alfons Verbruggen
-
Publication number: 20090252635Abstract: The invention provides a process of making porous structures or materials, including the colloidal processing (e.g. slip casting, pressure casting, tape casting or electrophoretic deposition) of solid particle emulsions to form a green body that can be directly sintered without a de-binding step.Type: ApplicationFiled: June 27, 2006Publication date: October 8, 2009Applicant: K.U.LEUVEN RESEARCH & DEVELOPMENTInventors: Bram Neirinck, Jozef Vleugels, Jan Fransaer, Omer Van Der Biest
-
Publication number: 20090208456Abstract: The present invention relates to pharmaceutical compositions for the treatment of prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyrimidine having the general formula (A), wherein the substituents are described in the specification. The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula, their pharmaceutically acceptable formulations and their use as a medicine or to treat or prevent viral infections.Type: ApplicationFiled: July 26, 2005Publication date: August 20, 2009Applicants: Gilead Sciences, Inc., K.U. Leuven Research & Development, Gerhard PuerstingerInventors: Gerhard Puerstinger, Choung U. Kim, Johan Neyts, David A. Oare
-
Publication number: 20090181882Abstract: The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).Type: ApplicationFiled: December 30, 2008Publication date: July 16, 2009Applicants: K.U. Leuven Research and Development, Aarhus Universitet, Aarhus University HospitalInventors: Greta Van Den Berghe, Steffen Thiel, Troels Krarup Hansen
-
Publication number: 20090149523Abstract: The present invention relates to the use of N-aminoimidazole or N-aminoimidazole-thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes.Type: ApplicationFiled: May 10, 2007Publication date: June 11, 2009Applicant: K.U.Leuven Research and DevelopmentInventors: Christophe Pannecouque, Wim Robberecht, Miguel Stevens
-
Patent number: 7520929Abstract: This invention consists of a modified gluten biopolymer for use in industrial applications, such as composites and foams. In the present work, the fracture toughness of the gluten polymer was improved with the addition of a thiol-containing modifying agent. This work also resulted in the development of a gluten biopolymer-modified fiber bundle, demonstrating the potential to process fully biodegradable composite materials. Qualitative analysis suggests that a reasonably strong interface between the natural fibers and biopolymer matrix can form spontaneously under the proper conditions. Therefore this invention relates to a modified gluten biopolymer for use in industrial applications, such as composites, stabilized foams and molded articles of manufactures. The present invention relates to a new gluten based biopolymer with modified properties, such as an increase in impact strength, and prepared by using thiol-containing molecules.Type: GrantFiled: September 26, 2003Date of Patent: April 21, 2009Assignees: K.U. Leuven Research & Development, University of ConnecticutInventors: Dara Woerdeman, Wim Veraverbeke, Ignace Verpoest, Jan Delcour, Richard S. Parnas
-
Patent number: 7514233Abstract: The present invention provides integrase interacting proteins including cofactors which promote strand transfer activity of viral integrase, more particularly HIV integrase, and methods and uses relating thereto. The present invention also relates to methods of identifying molecules interacting with integrase interacting protein and their use as an antiviral.Type: GrantFiled: September 26, 2003Date of Patent: April 7, 2009Assignee: K.U. Leuven Research & DevelopmentInventors: Zeger Debyser, Petr Cherepanov, Erik De Clercq